A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Alcon Reports Net Sales of $2.3 Billion in Q3-2023
Alcon reported Nov. 14 that its Q3-2023 net sales totaled $2.3 billion, an 8 percent increase (+9 percent cc) over $2.1 billion in Q3-2022.
Surgical net sales for implantables, consumables, and equipment/other were $1.3 billion, a 5 percent increase (+6 percent cc) over $1.2 billion in Q3-2022.
The company said implantables growth of 2 percent (+5 percent cc) was driven by demand for advanced technology intraocular lenses in international markets.
Consumables growth of 7 percent reflected demand for cataract and vitreoretinal consumables, particularly in international markets, and price increases.
Equipment/other growth of 4 percent (+5 percent cc) was fueled by demand for cataract equipment in international markets.
Vision Care net sales for contact lenses and ocular health were $1.0 billion, a 13 percent increase over $908 million in Q3-2022.
Alcon, a Swiss company with US headquarters in Fort Worth, Texas, tightened its full year guidance to $9.3 billion to $9.4 billion from previous guidance in August of $9.3 billion to $9.5 billion.
Iridex Posts Q3-2023 Revenue of $12.9 Million
Iridex, of Mountain View, California, reported Nov. 14 that its Q3-2023 revenue was $12.9 million, a 12 percent decrease from $14.6 million in Q3-2022.
The laser company said revenue for its Cyclo G6 product family was $3 million, a 12 percent decrease from $3.5 million in Q3-2022, due to reduced system sales.
Iridex sold 13,200 Cyclo G6 probes, for a 3 percent revenue increase and 3 percent unit decrease compared with Q3-2022.
The company sold 27 Cyclo G6 Glaucoma Laser Systems, compared with 54 in Q3-2022.
Retina product revenue in Q3-2023 was $7.9 million, a 10 percent decrease from $8.8 million year-over-year.
The company withdrew its revenue guidance, saying it could not predict the impact of reimbursement changes from five Medicare administrative contractors on sales of its glaucoma probes and systems.
Iridex had announced in late August that it was undertaking a review and evaluation of strategic alternatives to unlock shareholder value.
Lensar Posts Q3-2023 Revenue of $9.8 Million
Lensar, of Orlando, Florida, reported Nov. 9 that its Q3-2023 revenue was $9.8 million, a 26 percent increase over $7.7 million in Q3-2022.
The company said the growth was due primarily to increased system sales and procedure volume.
US procedure volume in Q3-2023 rose 16 percent, and overall procedure volume rose 15 percent (32,649 global procedures in Q3-2023 versus 28,453 in Q3-2022) despite a significant drop in South Korea procedure volume due to ongoing third-party payor reimbursement challenges.
Lensar noted that it had an installed base of 39 Ally systems, as of Sept. 30.